Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Prelude Therapeutics Inc (PRLD)

Prelude Therapeutics Inc (PRLD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering GlobeNewswire - Mon Apr 20, 5:30AM CDT

WILMINGTON, Del., April 20, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude” or the “Company”), a clinical-stage precision oncology company, today announced...

PRLD : 4.86 (-5.63%)
Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026 GlobeNewswire - Mon Apr 20, 5:00AM CDT

Data Demonstrate Potential for Differentiated Efficacy and Safety Profile, Including Complete Responses as Monotherapy in Multiple CDX and PDX Models of HR+/HER2- Breast Cancer  Prelude Remains on...

PRLD : 4.86 (-5.63%)
Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer GlobeNewswire - Wed Apr 15, 6:30AM CDT

WILMINGTON, Del., April 15, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude Therapeutics” or the “Company”), a clinical-stage precision oncology company, today...

PRLD : 4.86 (-5.63%)
Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting GlobeNewswire - Tue Mar 17, 3:31PM CDT

WILMINGTON, Del., March 17, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, today announced that a poster with preclinical data on the Company’s...

PRLD : 4.86 (-5.63%)
Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026 GlobeNewswire - Tue Mar 10, 6:01AM CDT

Received FDA clearance of Investigational New Drug application (IND) for PRT12396, mutant-selective JAK2V617F inhibitor in the first quarter of 2026 Phase 1 study of PRT12396 in patients with polycythemia...

PRLD : 4.86 (-5.63%)
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor GlobeNewswire - Tue Feb 3, 8:00AM CST

WILMINGTON, Del., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) cleared...

PRLD : 4.86 (-5.63%)
Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs GlobeNewswire - Sat Dec 6, 2025

First disclosure of PRT12396, a JAK2V617F-selective JH2 inhibitor demonstrates disease modifying potential in myeloproliferative neoplasms PRT12396 has completed GLP toxicology studies and is on track...

PRLD : 4.86 (-5.63%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Prelude Therapeutics Incorporated - PRLD PR Newswire - Thu Nov 20, 2025

NEW YORK , Nov. 20, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Prelude Therapeutics Incorporated ("Prelude" or the "Company") (NASDAQ: PRLD). Such investors...

PRLD : 4.86 (-5.63%)
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B FinancialNewsMedia - Wed Nov 19, 2025

EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:ALXO),(NASDAQ:ERAS),(NASDAQ:IMRX),(NASDAQ:PRLD) EQNX::TICKER_END

ONCY : 0.8899 (-1.12%)
IMRX : 5.22 (unch)
ALXO : 2.08 (+11.23%)
ERAS : 10.12 (-2.69%)
PRLD : 4.86 (-5.63%)
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B GlobeNewswire - Wed Nov 19, 2025

PALM BEACH, Fla., Nov. 19, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The precision oncology sector is experiencing unprecedented transformation as biomarker-driven therapies and...

ONCY : 0.8899 (-1.12%)
IMRX : 5.22 (unch)
ALXO : 2.08 (+11.23%)
ERAS : 10.12 (-2.69%)
PRLD : 4.86 (-5.63%)

Barchart Exclusives

JPMorgan vs. Bank of America: How the 2 Dividend-Paying Bank Stocks Stack Up in 2026 Barchart - Fri May 8, 6:00PM CDT
JPMorgan dominates on scale and profits, while Bank of America wins on value and yield. Here's which big bank stock deserves your money in 2026. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.